Alnylam Pharmaceuticals(US:ALNY)2022-04-28 13:14Financial Performance - Alnylam's Q1 2022 net product revenues were $186.9 million, a 38% increase compared to Q1 2021[55] - At constant exchange rates (CER), net product revenues grew by 43%[55] - Total revenues for Q1 2022 were $213.3 million, a 20% increase compared to Q1 2021[55] - At CER, total revenues grew by 24%[55] - Alnylam updates its full year 2022 net product revenue guidance to $870 million - $930 million[56] Product Performance - ONPATTRO global Q1 2022 net product revenues are not specified in the provided content, but it shows a YoY growth of 34% and a QoQ growth of -1%[15, 17] - GIVLAARI global Q1 2022 net product revenues were $15 million, with a YoY growth of 43% and a QoQ growth of -13%[21, 23] - OXLUMO global Q1 2022 net product revenues were $15 million, with a YoY growth of 59% and a QoQ growth of -24%[24, 26] Clinical Development - Enrollment is complete for the Patisiran Phase 3 study in ATTR amyloidosis patients with cardiomyopathy, with topline results expected mid-2022[29] - The Vutrisiran Phase 3 study in hereditary ATTR amyloidosis with polyneuropathy met its primary endpoint of change from baseline in mNIS+7 at Month 9[30] - Enrollment is complete for the Vutrisiran Phase 3 study in ATTR amyloidosis patients with cardiomyopathy, with topline results on the 30-month endpoint expected early 2024[46]